Soloff P H
Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA.
Bull Menninger Clin. 1998 Spring;62(2):195-214.
A pharmacological approach to treating patients with personality disorders (PD) is based on evidence that some dimensions of personality are mediated by variations in neurotransmitter physiology and are responsive to medication effects. Target symptoms for pharmacotherapy in the PD patient are derived from expressions of cognitive-perceptual, affective, and impulsive-behavioral dysregulation of central neurotransmitter functions. Pharmacotherapy is directed at state symptoms during periods of acute decompensation and at trait vulnerabilities, which represent the diathesis to future episodes. A basic assumption of this approach is that neurotransmitter biology transcends Axis I and Axis II definitions and that closely related symptoms may share a common pathophysiology, independent of categorical definition. A common pathophysiology implies the possibility of shared responsiveness to medication. Using a dimensional definition of symptom domains, the author has developed treatment algorithms for cognitive-perceptual symptoms, affective dysregulation, and impulsive-behavioral dyscontrol in personality disorder patients.
一种治疗人格障碍(PD)患者的药理学方法基于以下证据:人格的某些维度由神经递质生理学的变化介导,并对药物作用有反应。PD患者药物治疗的目标症状源于中枢神经递质功能的认知-感知、情感和冲动-行为失调的表现。药物治疗针对急性失代偿期的状态症状以及特质易感性,特质易感性代表未来发作的素质。这种方法的一个基本假设是,神经递质生物学超越了轴I和轴II的定义,并且密切相关的症状可能共享一种共同的病理生理学,而与分类定义无关。共同的病理生理学意味着对药物有共同反应的可能性。作者使用症状领域的维度定义,为人格障碍患者的认知-感知症状、情感失调和冲动-行为失控制定了治疗算法。